Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms.

Archives of toxicology - 1 Mar 2013

Daly Ann K

Abstract excerpt

Coumarin anticoagulants, which include warfarin, acenocoumarol and phenprocoumon, are among the most widely prescribed drugs worldwide. There is now a large body of published data showing that genotype for certain common polymorphisms in the genes encoding the target vitamin K epoxide reductase (G-1639A/C1173T) and the main metabolizing enzyme CYP2C9 (CYP2C9*2 and *3 alleles) are important determinants of the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biotransformation
Share to Cytochrome P450 Family 4
Share to Drug Dosage Calculations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Monitoring

Share to Hemorrhage

Share to International Normalized Ratio

Share to Vitamin K Epoxide Reductases

Share to Warfarin

Source

Identifiers

PMID: 23376975
DOI: 10.1007/s00204-013-1013-9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms.PMID 23376975Read ↗

Pharmacogenomics of anticoagulants: steps toward personal dosageSemantic proximity Read ↗

Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design.Semantic proximity Read ↗

Genetic determinants of acenocoumarol and phenprocoumon maintenance dose requirements.Semantic proximity Read ↗

Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon.Semantic proximity Read ↗

Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives.Semantic proximity Read ↗

Genotype-based dosing algorithms for warfarin therapy: data review and recommendations.Semantic proximity Read ↗

Pharmacogenetics of warfarin.Semantic proximity Read ↗

Role of Warfarin Pharmacogenetic Testing in Clinical PracticeSemantic proximity Read ↗

Genotype-guided coumarin dosing: where are we now and where do we need to go next?Semantic proximity Read ↗

Warfarin pharmacogenetics: does more accurate dosing benefit patients?Semantic proximity Read ↗

Warfarin pharmacogenomics.Semantic proximity Read ↗

The COAG and EU-PACT trials: what is the clinical benefit of pharmacogenetic-guided coumarin dosing during therapy initiation?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.